A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.

Recruiting now · Phase 3

Conditions studied: Rhabdomyosarcoma, Pediatric Cancer

In brief

The purpose is to explore the efficacy and safety of the SYSUCC-RMS regimen for pediatric RMS patients and to explore the impact of concurrent radiotherapy and chemotherapy on the survival rate of low-risk, medium risk, high-risk, and extremely high-risk patients in children.

Key facts

Study ID

NCT06836492

Run by

Yizhuo Zhang

People needed

300

Starts

2017-01-30

Expected to finish

2029-12-01

Last updated by the study team

2025-02-20

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 0 years < age < 18 years old, regardless of gender;
• Tumor patients diagnosed by histopathology or bone marrow cytology;
• Patients are treated for the first time;
• ECoG score ≤ 2;
• The expected survival time is more than 8 months;
• Patient's parent or guardian signs informed consent.

You may not qualify if…

• Combined with immunodeficiency disease
• Second tumor

Where it is running

• Suying Lu — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.